Vir Biotechnology (VIR) News Today $7.34 -0.03 (-0.41%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Has $42.14 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR)State Street Corp grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 10.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,625,533 shares of the company's stock after buying an additional 530,645 shares during the period. State Street CDecember 21 at 3:24 AM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 78.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,455 shares of the company's stock after selDecember 20 at 4:10 AM | marketbeat.comVir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18 at 6:18 PM | businesswire.comCautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial OutlookDecember 18 at 12:42 AM | markets.businessinsider.comVir receives FDA, EMA designations for tobevibart and elebsiranDecember 13, 2024 | markets.businessinsider.comVir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In JanuaryDecember 13, 2024 | seekingalpha.comVir gets FDA breakthrough therapy status for two drugsDecember 12, 2024 | msn.comVir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaDecember 12, 2024 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,134,276 shares of the company's stock after purchasing an aDecember 11, 2024 | marketbeat.comVir has positive readthrough from Janux data, says Morgan StanleyDecember 3, 2024 | markets.businessinsider.comJanux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A RideDecember 3, 2024 | msn.comJanux, Vir stocks rally on positive data for Janux drug JANX007December 2, 2024 | msn.comWill Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?December 1, 2024 | uk.finance.yahoo.comEnanta Pharmaceuticals (ENTA) Receives a Sell from J.P. MorganNovember 28, 2024 | markets.businessinsider.comVir Biotechnology's SWOT analysis: stock poised for growth amid clinical progressNovember 27, 2024 | investing.comVir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager ProgramsNovember 26, 2024 | finance.yahoo.comVir Biotechnology’s Promising Advancements in Hepatitis Treatments Justify Buy RatingNovember 22, 2024 | markets.businessinsider.comLeerink Partnrs Has Bearish Outlook for VIR FY2026 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Leerink Partnrs decreased their FY2026 earnings per share (EPS) estimates for shares of Vir Biotechnology in a report released on Wednesday, November 20th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings of (November 22, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for VIR FY2024 Earnings?Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings estimates for Vir Biotechnology in a research report issued to clients and investors on Wednesday, November 20th. HC Wainwright analyst P. Trucchio now anticipates that the companNovember 22, 2024 | marketbeat.comJ.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)November 22, 2024 | markets.businessinsider.comVir Biotechnology’s Promising Therapeutic Advancements Justify Buy RatingNovember 21, 2024 | markets.businessinsider.comHolding Pattern: Awaiting Clarity on Vir Biotechnology’s Potential Amid Promising Trials and Pending DataNovember 20, 2024 | markets.businessinsider.comVir Biotechnology: Promising Data and Strategic Developments Justify Buy RatingNovember 20, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)Needham & Company LLC reiterated a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday.November 20, 2024 | marketbeat.comEmpowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)Empowered Funds LLC reduced its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 33.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 329,781 shares of the company'sNovember 20, 2024 | marketbeat.comVir Biotechnology holds a virtual investor updateNovember 19, 2024 | markets.businessinsider.comVir Biotechnology announces results from SOLSTICE trialNovember 19, 2024 | markets.businessinsider.comVir Biotechnology gets positive opinion on orphan drug designation for TobevibarNovember 19, 2024 | markets.businessinsider.comVir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramNovember 18, 2024 | businesswire.comVir Biotechnology (VIR) Gets a Buy from BarclaysNovember 18, 2024 | markets.businessinsider.comVir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines AgencyNovember 18, 2024 | businesswire.comVir Biotechnology: Promising Hepatitis B Treatment Data Amid Cautious Optimism and Awaited MilestonesNovember 17, 2024 | markets.businessinsider.comVir Biotechnology (NASDAQ:VIR) Stock, Insider Trading ActivityNovember 16, 2024 | benzinga.comWhat's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?November 15, 2024 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.4% - Here's WhyVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.4% - Here's WhyNovember 15, 2024 | marketbeat.comVir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver MeetingNovember 15, 2024 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 39.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,383,029 shares of the coNovember 13, 2024 | marketbeat.comHold Recommendation for Vir Biotechnology Amid Cautious Optimism on Infectious Disease and Oncology ProspectsNovember 9, 2024 | markets.businessinsider.comVir Biotechnology participates in a conference call with JPMorganNovember 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)November 6, 2024 | markets.businessinsider.comFY2024 EPS Estimate for Vir Biotechnology Lowered by AnalystVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Analysts at HC Wainwright dropped their FY2024 earnings estimates for Vir Biotechnology in a report issued on Monday, November 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($3.70) per share for the yNovember 6, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of VIR FY2024 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for Vir Biotechnology in a research note issued on Sunday, November 3rd. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($4.02) per share for the yeNovember 6, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 1,403 SharesNovember 6, 2024 | insidertrades.comVir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay OffNovember 5, 2024 | seekingalpha.comVir Biotechnology price target lowered to $26 from $28 at BarclaysNovember 4, 2024 | markets.businessinsider.comVir Biotechnology’s Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy RatingNovember 4, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)HC Wainwright reiterated a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Monday.November 4, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Given New $26.00 Price Target at BarclaysBarclays reduced their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Monday.November 4, 2024 | marketbeat.comAnalysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest ResultsNovember 4, 2024 | finance.yahoo.comVir Biotechnology Third Quarter 2024 Earnings: Misses ExpectationsNovember 2, 2024 | finance.yahoo.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.490.60▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼45▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMVT News SRRK News CRSP News DNLI News TWST News VCEL News SWTX News KYMR News IOVA News BEAM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
